Search results

Found 245 pages
AUTHOR: Katrina Megget

Results per page

10 20 50 100

Sort by

Relevance Date

8 Oct 2008:

AtheroGenics goes bankrupt

US-based biopharmaceutical company AtheroGenics has filed for Chapter 11 bankruptcy citing a “substantial debt burden”. - News - PharmaTimes

by Katrina Megget

https://www.pharmatimes.com/news/atherogenics_goes_bankrupt_986651

2 Dec 2009:

Swine flu labelled a conspiracy

The swine flu pandemic has been named as the “most ambitious scam and corruption of our time” after pharma has been found to be in bed with the World Health Organisation. - News - PharmaTimes

by Katrina Megget

https://www.pharmatimes.com/news/swine_flu_labelled_a_conspiracy_984175

14 Oct 2008:

Januvia licence extended in Scotland

Merck Sharp & Dohme’s type 2 diabetes drug Januvia (sitagliptin) has been extended for use within NHS Scotland as a dual and triple therapy option. - News - PharmaTimes

by Katrina Megget

https://www.pharmatimes.com/news/januvia_licence_extended_in_scotland_986603

27 Aug 2010:

Janssen-Cilag appeals Velcade decision

Janssen-Cilag is to appeal the UK decision to restrictaccess to its multiple myeloma drug Velcade (bortezomib).  - News - PharmaTimes

by Katrina Megget

https://www.pharmatimes.com/news/janssen-cilag_appeals_velcade_decision_982529

11 Mar 2014:

UK to launch early access to drugs plan

UK plans to fast track access to drugs – in some cases up to ten years earlier – are expected to be announced imminently. - News - PharmaTimes

by Katrina Megget

https://www.pharmatimes.com/news/uk_to_launch_early_access_to_drugs_plan_1001654

8 Apr 2014:

BMS submits hep C drugs in the USA

Bristol-Myers Squibb has submitted new drug applications with US regulators for hepatitis C drugs daclatasvir and asunaprevir. - News - PharmaTimes

by Katrina Megget

https://www.pharmatimes.com/news/bms_submits_hep_c_drugs_in_the_usa_1001787

14 Oct 2008:

Abbott buys back $5 billion worth of stock

Abbott has announced it will repurchase $5 billion worth of the company’s shares in a bid to strengthen its stock, which has seen a 12% drop this year. - News - PharmaTimes

by Katrina Megget

https://www.pharmatimes.com/news/abbott_buys_back_$5_billion_worth_of_stock_986602

16 Mar 2015:

Valeant counterbids for Salix

It’s all change again in the fight for Salix Pharmaceuticals – last week’s $11 billion bid by Endo International has been binned in favour of rival bidder Valeant Pharmaceuticals International, which has put forward a revised $173-a-share offer

by Katrina Megget

https://www.pharmatimes.com/news/valeant_counterbids_for_salix_971189

16 Apr 2012:

AZ's CEO says he is staying

AstraZeneca’s chief executive David Brennan has maintained he will be staying in the top role despite speculation surrounding the company’s future. - News - PharmaTimes

by Katrina Megget

https://www.pharmatimes.com/news/azs_ceo_says_he_is_staying_977491

9 Oct 2009:

Pfizer’s HIV drug gets a positive boost

Pfizer’s HIV drug Selzentry (maraviroc) has been backed by a US Food and Drug Administration panel recommending broader use of the currently limited access drug. - News - PharmaTimes

by Katrina Megget

https://www.pharmatimes.com/news/pfizers_hiv_drug_gets_a_positive_boost_984483